Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 7, 2011

Asuragen pancreatic cancer assay found effective

Asuragen's microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.

Asuragen’s microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.

The data from the multicentre study involving 186 subjects showed that the miRNA-based molecular test will improve the diagnostic accuracy of fine-needle aspiration cytology on indeterminate and suspicious specimens.

miRInform Pancreas, along with standard fine-needle aspiration cytology, allows pancreatic ductal adenocarcinoma to be diagnosed with 92.5% accuracy, as compared to 80.2% for fine-needle aspiration cytology alone.

Brigham and Women’s Hospital Dr Darwin Conwell said that the microRNA-based molecular test helps to identify false negative cytology.

The molecular test will be available in the company’s CLIA Laboratory from 1 December 2011.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU